Introduction
The mouse Cyp2a gene subfamily encompasses four genes (Cyp2a4, Cyp2a5, Cyp2a12, and Cyp2a22) , whereas the human CYP2A gene subfamily has three genes (CYP2A6, CYP2A7, and CYP2A13) (Wang et al., 2003) . Human CYP2A6 and CYP2A13 are known to be functional, and they are most similar to mouse CYP2A5, with respect to tissue distribution and substrate specificity (Su et al., 2004) . Both CYP2A6 and CYP2A13 are expressed in the olfactory mucosa (OM) and other tissues of the respiratory tract, while CYP2A6 is also expressed in the liver; mouse CYP2A5 is expressed in many tissues, including tissues of the respiratory tract, liver, and kidney. CYP2A5 shares many substrates with CYP2A6 and/or CYP2A13, such as coumarin, nicotine, cotinine, testosterone, as well as the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and other nitrosamines (Su et al., 2004; Wong et al., 2005; Raunio et al., 2008a) .
Nicotine is the pharmacologically active (and addictive) ingredient in cigarette products.
Nicotine is also used as a therapeutic agent for smoking cessation, and it is being tested as a potential preventative agent for neurodegenerative diseases, both in animal models and in clinical trials (Quik et al., 2007; Ravina et al., 2003) . Nicotine can be metabolized via several pathways in humans, including 5'-hydroxylation to yield cotinine, catalyzed mainly by CYP2A6 (Nakajima et al., 1996; Messina et al., 1997) ; N-demethylation , also mediated by CYP2A6; N-oxidation (Cashman et al., 1992; Cashman 2000) , catalyzed by flavincontaining monooxygenase; and N-glucuronidation (Kuehl et al., 2003; Kaivosaari et al., 2007) , catalyzed by various UDP-glucuronosyltransferases. In humans, ~75% of administered nicotine is converted to cotinine (Hukkanen et al., 2005) , a gamma lactam metabolite formed via 5'-hydroxylation. Indeed, cotinine is used as a chemical marker for human exposure to cigarette smoking (de Leon et al., 2002) . Additionally, genetic polymorphisms in the human CYP2A6 This article has not been copyedited and formatted. The final version may differ from this version. JPET Fast Forward. Published on November 18, 2009 as DOI: 10.1124 at ASPET Journals on April 1, 2017 jpet.aspetjournals.org Downloaded from JPET #162610 5 gene have been linked to inter-individual differences in the rates of nicotine clearance (Benowitz et al., 2006) . Mouse CYP2A5 is also believed to play a major role in the clearance of nicotine and cotinine, based on in vitro data and in vivo pharmacological evidence (Raunio et al., 2008b; Siu et al., 2006; Siu and Tyndale, 2007) , although direct in vivo evidence, such as the disposition in a Cyp2a5-null mouse, has yet to be reported. However, a remarkable species difference exists between humans and mice in the rates of nicotine clearance, with the metabolism being much more rapid in mice than in humans. This notable species difference makes it difficult to extrapolate pharmacological and toxicological findings obtained in mouse experiments to human contexts. Furthermore, the rapid metabolism of nicotine in mice has hindered efforts to use this species for studies on the mechanisms of nicotine addiction, or for studies on the potential of nicotine as an agent for prevention of diseases such as Parkinson's disease (Quik et al., 2007) .
Biochemical studies have suggested that the species difference between mouse and humans in nicotine clearance is largely due to differences in the efficiencies of human CYP2A6 and mouse CYP2A5 in nicotine 5'-hydroxylation, with CYP2A5 being much more efficient than is CYP2A6 . Indeed, other mouse hepatic P450 enzymes appear to be either similar to, or less efficient than, human CYP2A6, with respect to their enzymatic activities toward nicotine Siu and Tyndale et al., 2007) . Thus, a Cyp2a5-null mouse will not only be valuable for determination of the specific roles of CYP2A5 in drug metabolism and toxicity in a mouse model, but it will also represent a more "humanized" mouse model that is suitable for various studies concerning the pharmacology of nicotine and cotinine. A Cyp2a5-knockout mouse model has not been described previously.
In the present study, we have generated a Cyp2a5-null mouse through homologous recombination in embryonic stem (ES) cells derived from the C57BL/6 (B6) mouse strain. Homozygous Cyp2a5-null mice were characterized for: viability and fertility; growth rates; potential compensatory expression in other enzymes that can influence nicotine clearance; and circulating levels of testosterone and progesterone, endogenous compounds that are among known CYP2A5 substrates. The Cyp2a5-null mice were then compared to the WT B6 mice, for their abilities to clear nicotine and cotinine in vivo, and for the activities of their hepatic microsomes to metabolize nicotine in vitro. Pharmacokinetic analyses were then performed, to determine the impact of the Cyp2a5 deletion on levels of nicotine and cotinine in the brain (the pharmacological target organ), the liver (the major site of metabolic clearance), and the blood (the medium for biomonitoring).
This article has not been copyedited and formatted. The final version may differ from this version. hydrogen tartrate, (-)-nicotine, ammonium acetate, and NADPH were purchased from SigmaAldrich (St. Louis, MO). The sources of testosterone, progesterone, 16α-hydroxy-progesterone, and all testosterone metabolite standards were the same as described previously (Ding and Coon 1988; 1994; Zhou et al., 2009 ). 3,4-13 C-progesterone was obtained from Cambridge Isotope
Laboratories (Andover, MA). All solvents (acetonitrile, methanol, and water) were of highperformance liquid chromatography (HPLC) grade (Fisher Scientific, Houston, TX).
Targeting vector construction. The targeting vector ( Fig. 1 ) was prepared in a pMClox-neo-lox vector (4.0 kb) (Millipore, Billerica, MA). It consists of a tk-neo-bpA cassette for the neomycin-resistance (neo) gene expression, using the thymidine kinase (tk) promoter; the neo was flanked by two loxP sites in the same orientation. A 1.6-kb Pst I fragment encompassing exons 6-8, and a 5.6-kb BamH I-EcoR I fragment of the 3'-flanking region, were obtained from the C57BL/6 (B6) mouse bacterial artificial chromosome (BAC) clone RP23-165I8 (BACPAC Resources, Oakland, CA), which contains Cyp2a5, but not Cyp2a4. The two fragments were cloned into the pMC-lox-neo-lox vector, which was linearized with Cla I, before electroporation into embryonic stem (ES) cells.
Electroporation and selection of ES cells. The Bruce4 (C57BL/6J-derived) ES cells (Kontgen et al., 1993) , kindly provided by Dr. Colin Stewart (National Cancer Institute, Frederick, MD), were used for electroporation, at the Transgenic and Knockout Core Facility of the Wadsworth Center. Recombinant ES cells were selected with the use of 250 µg/ml G418.
Positive ES cell clones were identified by PCR [using the primers 5'-ttagggcactgggtcacttc-3'
(upstream of the 1.6-kb Pst I fragment) and 5'-cgatctagaggtaccataacttcgt-3' (within the vector region), with an annealing temperature of 62°C], and was confirmed by Southern blot analysis This article has not been copyedited and formatted. The final version may differ from this version. Blastocyst injection and animal breeding. ES cells from positive clones were karyotyped, and the clone with the best karyotyping result was selected for expansion. ES cells were injected into the blastocysts from albino B6(Cg)-Tyrc-2J/J (Jackson Laboratory) female mice. Blastocysts were transferred into the uterus of a pseudopregnant B6CBAF1/J mouse, for generation of offspring. Male chimera pups were identified by their black eyes and coat color.
Adult chimeras were bred with C57BL/6J female mice, in order to produce germlinetransmission F1 mice that were heterozygous for the Cyp2a5-null allele. F2 homozygotes were used for breeding and characterization. B6 mice were used as WT controls in all experiments described. All procedures involving animals were approved by the Institutional Animal Care and Use Committee of the Wadsworth Center.
RNA-PCR.
Tissues for RNA or microsome preparation were all collected between 9:00 and 10:00 A.M. local time. Total RNA was isolated with use of the RNeasy Mini kit (QIAGEN, Valencia, CA). All RNA samples were treated with DNase I (Life Technologies, Carlsbad, CA) before reverse transcription (RT). RNA-PCR analysis was performed as previously described (Zhang et al., 2005) . Gene-specific PCR primers for amplification of exons 2 and 3 of Cyp2a5 were the same as described elsewhere (Zhuo et al., 2004) ; the primers for amplification of exons 8 and 9 were 5'-gatgacaagggacagtttaagaagaa-3'and 5'-gtgtaggttggtgggatcgtgg-3' (with an annealing temperature of 66°C). PCR products were validated by sequence analysis. Methods for real-time PCR analysis of CYP2G1 and CYP2A12 expression are described in the Supplemental
Materials.
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For plasma samples, 0.1 ng cotinine-d 3 was added as internal standard to 10 µl of plasma, which had been diluted in 1.0 ml 0.6 M phosphate buffer, pH 6.8, as described before (Heavner et al., 2005) . The resultant mixture was extracted with an Isolute Extraction Cartridge (C18; 1 ml/100 mg) (Biotage, Charlottesville, VA). The samples were eluted with 1 ml methanol, dried under nitrogen, and then reconstituted with 50% (v/v) methanol in water for LC/MS analysis.
The recovery of added nicotine and cotinine standards in blank plasma was > 80%, at all concentrations tested. For tissue sample preparation, brain and liver (~ 400 mg each) were homogenized in 3 ml saline (0.9% NaCl), followed by addition of 0.1 ng cotinine-d 3 . The mixtures were centrifuged, at 3000 g, for 10 min, and the supernatant was then extracted with an Isolute Extraction Cartridge (C18; 3 ml/100 mg), as described above for plasma samples. The recovery of added standards in blank tissues was >75%, at all concentrations tested.
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The levels of nicotine and cotinine were determined using a LC/MS system composed of an Agilent 1200 Series HPLC and an ABI 4000 Q-Trap mass spectrometer (Applied Biosystems, Foster City, CA), fitted with a 5-µm Gemini C18 column (50 x 2.0 mm). The samples were eluted at a flow rate of 0.2 ml/min, with solvent A (10 mM ammonium acetate in water) and solvent B (100% acetonitrile); the column was equilibrated with 100%A for 1 min, and the solvent gradient consisted of linear increases from 0%B to 100%B between 1 and 8 min, In vitro metabolism of testosterone and nicotine. Microsomal preparation was carried out essentially as described previously (Ding and Coon, 1990) ; the post-microsomal supernatant fraction was used as cytosol. Metabolism of testosterone was assayed essentially as described conditions that support constant rates of product formation, according to a protocol described previously (Siu et al., 2006) . The reaction was stopped by the addition of 1 ml methanol (containing 1 ng cotinine-d 3 ), and the mixture was centrifuged, in order to precipitate protein.
The supernatant was dried under nitrogen, and then reconstituted with 50% (v/v) methanol in water, for the measurement of cotinine by LC/MS analysis (as described above for the pharmacokinetics of plasma cotinine). Metabolite standard was added to reaction mixtures containing boiled microsomes, with recoveries being > 85% at all concentrations tested.
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Results

Generation and characterization of the Cyp2a5-null mouse
The structures of the WT Cyp2a5 allele, the targeting construct, and the targeted Cyp2a5-null allele are shown in Figure 1 (panels A, B, and C). A Cyp2a5 BAC genomic clone, isolated from the B6 strain, was used for construction of the targeting vector. The strategy used for targeted disruption of the mouse Cyp2a5 gene by homologous recombination in ES cells was to replace the last exon (exon 9), which encodes the active-site CYS residue, with a neomycinresistance gene. ES cells from a homologous recombinant clone (clone #221) were used for subsequent injection into the blastocyst cavity of albino B6(Cg)-Tyrc-2J/J embryos, from which a chimeric male was generated. When bred with WT B6 females, the chimera exhibited germline transmission. The absence of random integration of the targeting construct was confirmed by the use of both internal (Probe I) and external (Probe E) probes for Southern blot analysis (data not shown). Homozygous Cyp2a5-null mice (Cyp2a5 -/-) were produced by crossbreeding between heterozygous littermates (Cyp2a5 +/-). Homozygotes, heterozygotes, and WT littermates were identified by the presence of the characteristic bands for the WT (7-kb) and the Cyp2a5-null (4-kb) alleles, on Southern blots (Fig. 1D) . As a control, the integrity of the Cyp2a4/12 genes, which are highly similar to Cyp2a5 in genomic structure, is confirmed by the detection of the unique 2-kb genomic fragment, in mice of all three genotypes.
The absence of Cyp2a5 expression in various tissues of the Cyp2a5-null mice was confirmed by RNA-PCR, with use of two sets of gene-specific primers, which are complementary to sequences near either the 5'-end (E2-E3) or the 3'-end (E8-E9) of the CYP2A5 transcript. The results (Fig. 1E) indicated that neither the full-length CYP2A5 mRNA, nor a truncated CYP2A5 mRNA containing the first eight exons (which are intact), was present at detectable levels, in any of the tissues examined, of either male or female Cyp2a5-null mice.
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Homozygous breeding pairs were established, to produce Cyp2a5-null mice for subsequent studies.
Given our previous finding of a neighboring effect of Cyp2g1 gene disruption on the expression of the [downstream] Cyp2a5 gene (Zhuo et al., 2004) , we examined the potential effects of the disruption to Cyp2a5, on the expression of the neighboring Cyp2g1. We found that there was no significant difference between Cyp2a5-null and WT mice, in CYP2G1 mRNA levels in the olfactory mucosa, a site where CYP2G1 is uniquely expressed (Supplemental Fig.   1 ). Thus, the genomic disruption at Cyp2a5 exon 9 did not lead to noticeable changes in the expression of the upstream Cyp2g1 gene.
The expression of various Cyp2b genes, which are located further upstream of the Cyp2g1 gene, also appeared to be unaffected by the neo insertion, as exemplified by the results from immunoblot analysis of CYP2B protein expression (Supplemental Figure 2) . Notably, immediately downstream of Cyp2a5 is a cluster of Cyp2a genes and pseudogenes, including (in order of increasing distance from Cyp2a5) Cyp2a22, Cyp2a12 , and Cyp2a20-ps, with Cyp2a23-ps, a pseudogene, located at a distance of >100 kb from Cyp2a5 (Wang et al., 2003) . (Su et al., 2004) . Hepatic expression of Cyp2a12 was also not different between WT and Cyp2a5-null mice (data not shown), thus further confirming the absence of any neighboring effects of the neo insertion.
To examine whether the loss of Cyp2a5 expression in the liver led to compensatory increases in the expression of other biotransformation genes, we compared hepatic microsomal levels of several P450 proteins, namely, CYP2B, 2C, and 3A, as well as CPR, UGT1A, and UGT2B proteins, between Cyp2a5-null and WT mice. We found that the expression levels were similar between WT and Cyp2a5-null mice for each of these enzymes, in liver microsomes (Supplemental Fig. 2 ). Furthermore, we examined the metabolism of testosterone, a common substrate for multiple P450 enzymes, in liver microsomal reactions (Table 1) . We found that, whereas the rates of formation of 15β-OH-testosterone, a testosterone metabolite known to be produced by CYP2A5, were lower (by ~50%), the rates of formation of two major testosterone metabolites, 16α-OH-testosterone and 6β-OH-testosterone, the respectively preferred products formed by CYP2D9 (Wong et al., 1987) and CYP3A (Yanagimotoy et al., 1992) , were not changed, in the Cyp2a5-null mice, as compared to WT mice. In other studies not shown, we also observed lower rates of formation of 15α-OH-testosterone (also a CYP2A5 product), but not 16β, 6α, or 11α-OH testosterone. Consistent with the lack of a substantial difference in the overall rate of hepatic microsomal testosterone metabolism in vitro, there was no significant difference in circulating testosterone levels between WT males and Cyp2a5-null males (Supplemental Fig.   3A ). Similarly, there was also no significant difference in circulating progesterone levels between WT females and Cyp2a5-null females (Supplemental Fig. 3B ). These in vivo results indicate that, although CYP2A5 is active toward testosterone and progesterone (Gu et al., 1999) , This article has not been copyedited and formatted. The final version may differ from this version. it does not play a major role in the systemic clearance of testosterone or progesterone in the WT mice.
Role of CYP2A5 in the metabolic clearance of nicotine and cotinine
Systemic clearance of nicotine was compared between Cyp2a5-null and WT mice, with nicotine administered at either 1 mg/kg ( Fig. 2A) or 5 mg/kg (Fig. 2B) . As expected, clearance of nicotine in the WT mouse was very rapid, with a t 1/2 value of ~13 min following an i.p. injection at a dose of 1 mg/kg, and a t 1/2 value of ~70 min following an i.p. injection at the higher dose, 5 mg/kg (Table 2) . Nicotine clearance was significantly slower (by >70% in CL/F values) in the Cyp2a5-null mice, with concomitant 3.2-fold and 6.1-fold increases in the values for C max and AUC, respectively, at a dose of 1 mg/kg, and 3.4-fold and 2.7-fold increases in the values for C max and AUC, respectively, at a dose of 5 mg/kg. Increases in the t 1/2 value were also observed:
2.8-fold and 1.4-fold, for nicotine doses of 1 mg/kg and 5 mg/kg, respectively. Consistent with the notion that CYP2A5 is the low-Km enzyme in metabolizing nicotine, the impact of Cyp2a5 deletion on nicotine clearance was more pronounced at the 1 mg/kg dose than at the 5 mg/kg dose, as indicated by the greater magnitude (low-dose group vs high-dose group) of differences between null and WT mice, in both AUC (6.1-fold vs 2.7-fold, respectively) and t 1/2 (2.8-fold vs 1.4-fold, respectively). A further examination of the AUC values obtained at the two nicotine doses indicated a greater difference in the WT mice (>8-fold, high-dose/low-dose) than in the Cyp2a5-null mice (<4-fold); this result is consistent with a more efficient clearance in the WT mice than in the Cyp2a5-null mice, at the low dose.
The formation and clearance of cotinine, the main circulating metabolite of nicotine, were also monitored in nicotine-treated mice. The AUC and C max values for cotinine were much higher (>24-fold and >6-fold, respectively) than the corresponding values for nicotine, in WT This article has not been copyedited and formatted. The final version may differ from this version. The lower rate of cotinine clearance, as a result of the Cyp2a5 deletion, was confirmed by additional studies in which circulating levels of cotinine were determined for cotinine-treated WT and Cyp2a5-null mice (Fig. 2C) . As shown in Table 3 , the rate of cotinine clearance was significantly lower (by 74% in CL/F value), whereas the AUC (by 3.7-fold) and t 1/2 (by 2-4-fold)
values were higher, in the Cyp2a5-null mice than in the WT mice, at a cotinine dose of 1 mg/kg.
Interestingly, in cotinine-treated mice, the lower rates of cotinine clearance in the Cyp2a5-null mice were accompanied by only marginally higher (1.3-fold; p > 0.05) cotinine C max values, as compared to values for WT mice; this result can be explained by the much slower rate of firstpass metabolism of cotinine, as compared to metabolism of nicotine, in the liver.
For determination of the role of CYP2A5 in the regulation of tissue levels of nicotine and cotinine, a pharmacokinetic study was also carried out for liver, the main metabolic organ, and for brain, the target organ, with nicotine administered at 1 mg/kg. As shown in Figures 2, panels D and E, the concentration-time curves for tissue nicotine and cotinine levels were similar between the two organs, and also respectively similar to the curves determined for circulating nicotine and cotinine levels: much higher levels of nicotine, and much lower levels of cotinine, were seen in both liver and brain of the Cyp2a5-null mice than in liver and brain of the WT mice, at multiple time points after dosing. A further examination of the pharmacokinetic parameters for tissue nicotine and cotinine (Table 4) confirmed that CYP2A5 has a major impact on the bioavailability of nicotine and cotinine in the brain and the liver. In the Cyp2a5-null mice, the tissue levels of nicotine were higher in both liver (2.3-fold higher AUC, 1.2-fold higher C max )
This article has not been copyedited and formatted. The final version may differ from this version. JPET #162610 18 and brain (2.7-fold higher AUC, 2.0-fold higher C max ), whereas tissue levels of cotinine were lower in both organs (>75% lower C max , and 20-30% lower AUC), as compared to the levels for WT mice (Table 4) .
Overall, the CYP2A5-associated pharmacokinetic changes for tissue nicotine and cotinine (Table 4 ) are similar to the changes seen in plasma (Table 2) , and they are also comparable between brain and liver. This pattern is consistent with the notion that the impact of CYP2A5 is on systemic clearance, rather than on tissue distribution. In that context, the cotinine/nicotine abundance ratios were much higher for plasma than for liver and brain, in either WT or Cyp2a5-null mice; however, the abundance ratios were uniformly decreased in the Cyp2a5-null mice (Supplemental Table 3 ). Notably, tissue nicotine and cotinine levels were found to differ somewhat between brains and livers: AUC and C max values for both nicotine and cotinine were higher in the liver than in the brain, for either mouse strain (Table 4 ). This tissue difference can be explained partly by the fact that the liver is the portal-of-entry organ for intraperitoneally injected nicotine, and by the fact that the bulk of the cotinine was produced in the liver.
Interestingly, at a nicotine dose of 1 mg/kg, the tissue/plasma abundance ratios for nicotine were higher in the WT mice than in the Cyp2a5-null mice, whereas the ratios for cotinine were similar between the WT and Cyp2a5-null mice (Supplemental Table 4 ). The lower tissue/plasma abundance ratios for nicotine, but not for cotinine, in the Cyp2a5-null mice can likely be explained by a saturation of tissue binding for nicotine, but not for cotinine, given the fact that tissue levels of nicotine (but not the levels of cotinine) were much higher in the null mice, than in the WT mice.
The lower rates of nicotine clearance in the Cyp2a5-null mice were likely due to the loss of CYP2A5-mediated cotinine formation in the liver; that notion is supported by results from in This article has not been copyedited and formatted. The final version may differ from this version. vitro studies using hepatic microsomes from WT and Cyp2a5-null mice. Cotinine, formed through nicotine C-5'-oxidation (Fig. 3) , is the major metabolite of nicotine in mouse hepatic microsomal reactions, as indicated by the relative abundances of all metabolites detected by LC-UV at 254 nm (data not shown). The conversion of the reactive intermediate to the stable cotinine was aided by the inclusion of aldehyde oxidase (contained in liver cytosol) (Beedham et al., 1987) . As shown in Table 5 , the rates of cotinine formation were 85% and 73% lower for hepatic microsomes from the Cyp2a5-null mice than for hepatic microsomes from WT mice, at respective nicotine concentrations of 1 and 10 µM. Notably, the CYP2A5 contribution to microsomal nicotine metabolism in the WT mice was greater at the lower substrate concentration
(1 µM), a result further supporting the proposal that CYP2A5 is the low-Km enzyme in metabolizing nicotine.
We detected two other nicotine metabolites in mouse hepatic microsomal reaction mixtures (Fig. 3) . One, which was detected only when KCN was included in the reaction mixture, was identified as a cyanide adduct (m/z = 188), given the characteristic neutral loss of an HCN motif (m/z = 27), and the features of other fragment ions in the product ion spectrum of the metabolite (not shown). The formation of the cyanide adduct indicated the presence of an iminium ion intermediate, which we propose to be the dihydropyrolium ion that is formed via the initial CYP2A5-mediated 5'-hydroxylation of nicotine (Fig. 3) . The other metabolite (m/z = 149) had a mass fragmentation pattern consistent with that of nornicotine, which is formed from nicotine N-demethylation; notably, this metabolite does not represent a contaminant, given that it was not detected in zero-minute incubations. The roles of CYP2A5 in the formation of these apparently less abundant metabolites were not determined.
Discussion
The in vivo role of CYP2A5 in nicotine and cotinine clearance has recently been studied by others, who made use of either CYP2A5 chemical inhibitors (Raunio et al., 2008b) , or mouse strains (B6 and DBA/2) that have allelic differences in the structure and function of the CYP2A5
protein (Siu and Tyndale, 2007) . Pharmacokinetic parameters for plasma nicotine and cotinine were determined both in the study by Siu and Tyndale (2007) and in the present study; therefore, it is tempting to compare the results from these two studies. However, although B6 WT mice were treated with nicotine and cotinine (both at 1 mg/kg) in both studies, the experiments that correspond between the two studies in terms of compound and dose did not yield fully comparable results, given that the compounds were administered subcutaneously in the earlier study, but i.p. in ours. An examination of the pharmacokinetics data from the two studies indicates a difference in clearance rate, e.g., with the CL/F, AUC, and C max values for nicotine being 5.2 ± 0.2 ml/min, 80.8 ± 3.2 ng*h/ml, and 160 ± 15 ng/ml, respectively, following s.c.
injection (their study), and 31.9 ± 2.5 ml/min, 12.7 ± 0.5 ng*h/ml, and 43.2 ± 7.9 ng/ml, respectively, following i.p. injection (our study). This difference in clearance rates can be explained by the essential role of hepatic P450 enzymes in nicotine clearance and the differing proportions of the injected dose that are subjected to hepatic first-pass metabolism. While essentially all of the i.p.-injected dose of nicotine would be subjected to first-pass metabolism in the liver, before appearing in the systemic circulation, only a proportion of the s.c.-injected dose of nicotine would be distributed to the liver in each pass.
The study design of Siu and Tyndale (2007) also differed from that of the present study, in that total (conjugated and unconjugated) nicotine and cotinine were determined there, but only unconjugated compounds were determined here. The extent of glucuronidation of nicotine or cotinine in mice is not known (Siu and Tyndale, 2007) . In earlier work, UGT activities toward nicotine and cotinine had not been detected in mouse liver microsomes in vitro (Ghosheh and Hawes 2002) . Therefore, it is unlikely that the use or non-use of a de-conjugation step, between these two pharmacokinetics studies, would have affected the experimental outcome to any large extent.
Interestingly, despite the difference in the route of injection (s.c. vs i.p.) between the two studies, and the large differences in pharmacokinetic parameters seen for nicotine clearance, essentially identical pharmacokinetic parameters were seen for cotinine clearance (after comparable cotinine injections at 1 mg/kg to WT B6 mice) in the two studies. This apparent independence on the injection route, for cotinine clearance, is consistent with a rate of hepatic cotinine metabolism that is much lower than the rate of hepatic nicotine metabolism (as was shown by Siu and Tyndale, 2007) . Although the high-affinity Km values for B6 hepatic microsomal metabolism of nicotine and cotinine were similar (11.4 and 9.5 µM, respectively),
the Vmax values differed by >10-fold (0.50 and 0.04 nmol/min/mg). Thus, a much smaller proportion of the dose will be removed through first-pass clearance for i.p.-injected cotinine than for i.p.-injected nicotine; conversely, given the overall differences in clearance rate (slower for cotinine than for nicotine), the majority of s.c.-injected cotinine will eventually have a chance to pass through liver, and be metabolized by hepatic CYP2A5.
The lower rate of nicotine clearance in the Cyp2a5-null mice was accompanied by a lower level of cotinine formation, as compared to the values for WT mice. Notably, the impact of the Cyp2a5 deletion on nicotine AUC values (2.7-fold to 6.1-fold increases, null vs WT), and the impact of the Cyp2a5 deletion on cotinine C max values (56-67% reductions), an impact that mainly reflects the lower rate of nicotine metabolism, were more robust than was the impact on cotinine AUC values (18-35% reductions); the latter can be influenced by both rates of cotinine formation and rates of cotinine metabolism, in nicotine-teated mice. These findings relating to Human CYP2A6 is less efficient than is CYP2A5 in the metabolism of nicotine;
heterologously expressed CYP2A6 was found to have a Km value of 144 µM and a Vmax/Km value of 0.01 in nicotine C-5'-oxidation, whereas heterologously expressed CYP2A5 had a Km value of 7.7 µM and a Vmax/Km value of 0.20 . In liver microsomes from WT B6 mice, a high-affinity component (Km 11.4 µM) and a low affinity component (Km 306 µM) were identified, with CYP2A5 being apparently responsible for the high-affinity site (Siu and Tyndale, 2007) . Thus, in terms of the pharmacokinetics of nicotine clearance, the Cyp2a5-null mouse more closely resembles humans than does the WT B6 mouse. The residual activities toward nicotine in the Cyp2a5-null mice are likely contributed by other P450 enzymes that have either low affinity or low efficiency for this reaction, particularly members of the mouse Cyp2b subfamily (Siu and Tyndale, 2007) . In this context, human CYP2B6 and rat CYP2B1/2 have been found to be active in nicotine 5'-oxidation (Nakayama et al., 1993; Schoedel et al., 2001; Yamazaki et al., 1999) . Efforts are underway to prepare a CYP2A6-humanized mouse model, to enable direct study of CYP2A6-mediated nicotine metabolism in vivo.
It is important that we understand the impact of systemic metabolism on tissue levels of nicotine and cotinine in the brain, the pharmacological target organ for nicotine. Although cotinine does not have the same drug action as does nicotine, it does have the potential to modulate nicotine action, through its binding to epibatidine-sensitive nicotinic receptors (Vainio and Tuominen, 2001 ). Our observation of much higher (assuming that 1 g tissue is equivalent to 1 ml plasma) brain tissue levels than plasma levels, for nicotine, most likely reflects the higher tissue binding of nicotine in brain, as compared to plasma. In contrast, cotinine levels in the brain were actually slightly lower than levels in the plasma, of nicotine-treated mice. This finding may be explained by the slow rate of cotinine metabolism (relative to the rate of nicotine metabolism)
in the liver; it may also reflect rate limitations for penetration of the blood-brain barrier by cotinine (Riah et al., 1998) . Our findings concerning the effects of the Cyp2a5 gene deletion on nicotine and cotinine levels, and on the cotinine/nicotine abundance ratios, in the brains and plasma of nicotine-treated mice, should be taken into account, when predictions are made, on the basis of the measurable plasma levels, for brain levels of nicotine and cotinine, in nicotineexposed individuals.
The neuroprotective effects of nicotine against chemically induced neurotoxicity have been consistently demonstrated in experimental rat and monkey models, but conflicting results have been found in mice (Quik et al., 2007) . Nicotine clearance is much faster in mice than in humans, monkeys, and rats; it is conceivable that we are not able to maintain adequate levels of nicotine in the mouse brain for a sufficiently long period to enable effective neuroprotection, particularly for chronic effects involving nicotine-induced alterations in gene expression. Our finding, that plasma nicotine t 1/2 values, as well as brain nicotine levels, are significantly higher in nicotine-treated Cyp2a5-null mice than in the similarly dosed WT mice, suggests that the Cyp2a5-null mouse model is valuable for efforts to establish whether effective neuroprotection by nicotine can be achieved in mouse models through suppression of systemic clearance.
In summary, several features of our Cyp2a5-null mouse make it a suitable model for applications in drug metabolism and toxicology research. These features include the B6 genetic background; the specific deletion of the single mouse Cyp2a gene (sparing Cyp2a4 and 
